Prelude Therapeutics Inc (PRLD) Form 8-K — May 12, 2026
Prelude Therapeutics reported its financial results for the first quarter of 2026, showing a significant decrease in net loss to $10.4 million, or $0.13 per share, compared to $32.1 million, or $0.42 per share, in the prior year period. This improvement is primarily due to a decrease in R&D and G&A expenses. The company has initiated enrollment in a Phase 1 study of PRT12396, a mutant-selective JAK2V617F inhibitor, for patients with polycythemia vera (PV) and myelofibrosis (MF). This is a positive step forward in the clinical development of the drug.
Key figures
- Revenue
- 4580
- Total Debt
- 0
- Cash Position
- 84800
- Gross Proceeds
- 90000
- Shares Outstanding
- 82519981
Price after filing
Close on the filing date to close N calendar days later (from $4.64). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.